Next Article in Journal
Adjuvant Systemic Chemotherapy for Stages II and III Colon Cancer after Complete Resection: A Clinical Practice Guideline
Previous Article in Journal
A User’s Guide to Cannabinoid Therapies in Oncology
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 23
Issue 6
10.3747/co.23.3405
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Emerging Therapies for the Treatment of Relapsed or Refractory Follicular Lymphoma

by
D. MacDonald
1,*,
A. Prica
2,
S. Assouline
3,
A. Christofides
4,
T. Lawrence
5 and
L.H. Sehn
6
1
Division of Hematology, Dalhousie University, and QEII Health Sciences Centre, Halifax, NS, Canada
2
Department of Medical Oncology, University of Toronto, and Princess Margaret Hospital, Toronto, ON, Canada
3
Department of Oncology, McGill University, and Jewish General Hospital, Montreal, QC, Canada
4
mpact Medicom Inc., Toronto, ON, Canada
5
Hoffmann–La Roche, Mississauga, ON, Canada
6
Division of Medical Oncology, University of British Columbia, and BC Cancer Agency, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2016, 23(6), 407-417; https://doi.org/10.3747/co.23.3405
Submission received: 15 September 2016 / Revised: 12 October 2016 / Accepted: 18 November 2016 / Published: 1 December 2016

Abstract

With no treatment standard having been established for relapsed and refractory follicular lymphoma, a number of therapeutic approaches are used in Canada. In patients who relapse early or who eventually become resistant to subsequent treatment, prognosis is poor, and new approaches are needed. A number of novel therapies are being examined in this setting, including monoclonal antibodies, immunoconjugates, immunomodulatory agents, and signal transduction inhibitors. With the body of evidence for those emerging therapies accumulating and the standard upfront treatment changing from rituximab and chop (cyclophosphamide–doxorubicin–vincristine–prednisone) or rituximab and cvp (cyclophosphamide–vincristine–prednisone) to bendamustine and rituximab, treatment decisions in the relapsed and refractory setting have become more complex. The choice of subsequent treatment must consider type of upfront treatment; duration of remission; and patient-related factors such as age, comorbidities, and treatment preferences. This paper summarizes the evidence for novel therapies and proposes recommendations for subsequent treatment options by remission duration after induction and maintenance.
Keywords: follicular lymphoma; relapsed disease; refractory disease; novel treatments; emerging therapies follicular lymphoma; relapsed disease; refractory disease; novel treatments; emerging therapies

Share and Cite

MDPI and ACS Style

MacDonald, D.; Prica, A.; Assouline, S.; Christofides, A.; Lawrence, T.; Sehn, L.H. Emerging Therapies for the Treatment of Relapsed or Refractory Follicular Lymphoma. Curr. Oncol. 2016, 23, 407-417. https://doi.org/10.3747/co.23.3405

AMA Style

MacDonald D, Prica A, Assouline S, Christofides A, Lawrence T, Sehn LH. Emerging Therapies for the Treatment of Relapsed or Refractory Follicular Lymphoma. Current Oncology. 2016; 23(6):407-417. https://doi.org/10.3747/co.23.3405

Chicago/Turabian Style

MacDonald, D., A. Prica, S. Assouline, A. Christofides, T. Lawrence, and L.H. Sehn. 2016. "Emerging Therapies for the Treatment of Relapsed or Refractory Follicular Lymphoma" Current Oncology 23, no. 6: 407-417. https://doi.org/10.3747/co.23.3405

APA Style

MacDonald, D., Prica, A., Assouline, S., Christofides, A., Lawrence, T., & Sehn, L. H. (2016). Emerging Therapies for the Treatment of Relapsed or Refractory Follicular Lymphoma. Current Oncology, 23(6), 407-417. https://doi.org/10.3747/co.23.3405

Article Metrics

Back to TopTop